Top

Clinical and Translational Oncology

Published in:

Open Access 01-09-2018 | Research Article

Histopathologic analysis of stage pT1b kidney neoplasms for optimal surgical margins of nephron-sparing surgery

Authors: G. Li, Q. Luo, Z. Lang, Y. Li, A. Wang, K. Wang, Y. Niu

Published in: Clinical and Translational Oncology | Issue 9/2018

Abstract

Objective

To evaluate the pathological features and define the optimal surgical margins (SM) of nephron-sparing surgery (NSS) for kidney neoplasms 4–7 cm (stage pT1b) on preoperative imaging.

Materials and methods

The retrospective study included 748 patients who were diagnosed stage pT1b renal tumors and underwent either radical nephrectomy (RN, n = 475) or NSS (n = 273) from January 2004 to March 2017. The tumor size, pathological subtype, Fuhrman grade, status of peritumoral pseudocapsule (PC) and tumor multifocality were recorded. The relationship between peritumoral PC and positive SM was calculated statistically by Fisher’s exact probability test.

Results

The mean tumor diameter was 5.4 cm (range: 4.1–7.0 cm), 65 (8.7%) cases were discovered with multifocal lesions and 686 (91.7%) were surrounded with peritumoral PC in all 748 specimens. 57 (8.3%) of 686 cases were proved with tumor infiltrated beyond PC [infiltration (+)], and the presence of PC infiltration (+) was significantly correlated with positive SM (p = 0.016). The infiltrative depth of tumor cells into renal parenchyma beyond PC was all limited in 3 mm and the proportion of ≤ 1, 1–2 and 2–3 mm was 21.1% (12/57), 59.6% (34/57) and 19.3% (11/57), respectively.

Conclusions

Our report indicates a 3 mm excisional margin is acceptable to ensure negative SM when operating NSS on stage pT1b kidney neoplasms.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed

Simmons MN, Weight CJ, Gill IS. Laparoscopic radical versus partial nephrectomy for tumors > 4 cm: intermediate-term oncologic and functional outcomes. Urology. 2009;73(5):1077–82.CrossRefPubMed

Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. J Urol. 2011;186(2):394–9.CrossRefPubMed

Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg. 2004;93(2):88–96.CrossRefPubMed

Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol. 2000;163(2):442–5.CrossRefPubMed

Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors–is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181(1):55–61 (discussion 61–52).CrossRefPubMed

Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004;171(3):1066–70.CrossRefPubMed

Joniau S, Vander Eeckt K, Srirangam SJ, Van Poppel H. Outcome of nephron-sparing surgery for T1b renal cell carcinoma. BJU Int. 2009;103(10):1344–8.CrossRefPubMed

Lee HJ, Liss MA, Derweesh IH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol. 2014;24(5):448–52.CrossRefPubMed

10.

Capitanio U, Terrone C, Antonelli A, Minervini A, Volpe A, Furlan M, Matloob R, Regis F, Fiori C, Porpiglia F, Di Trapani E, Zacchero M, Serni S, Salonia A, Carini M, Simeone C, Montorsi F, Bertini R. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a–T1b renal mass and normal preoperative renal function. Eur Urol. 2015;67(4):683–9.CrossRefPubMed

11.

Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008;179(6):2158–63.CrossRefPubMedPubMedCentral

12.

Kang HW, Lee SK, Kim WT, Yun SJ, Lee SC, Kim WJ, Hwang EC, Kang SH, Hong SH, Chung J, Kwon TG, Kim HH, Kwak C, Byun SS, Kim YJ. Surgical margin does not influence recurrence rate in pT1 clear cell renal cell carcinoma after partial nephrectomy: a multicenter study. J Surg Oncol. 2016;114(1):70–4.CrossRefPubMed

13.

Shah PH, Moreira DM, Okhunov Z, Patel VR, Chopra S, Razmaria AA, Alom M, George AK, Yaskiv O, Schwartz MJ, Desai M, Vira MA, Richstone L, Landman J, Shalhav AL, Gill I, Kavoussi LR. Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. J Urol. 2016;196(2):327–34.CrossRefPubMed

14.

Kryvenko ON. Positive surgical margins increase risk of recurrence after partial nephrectomy for high risk renal tumors. Shah PH, Moreira DM, Okhunov Z, Patel VR, Chopra S, Razmaria AA, Alom M, George AK, Yaskiv O, Schwartz MJ, Desai M, Vira MA, Richstone L, Landman J, Shalhav AL, Gill I, Kavoussi LR. J Urol. 2016 Aug;196(2):327-34. Urol Oncol. 2017;35(6):449–50.CrossRefPubMed

15.

Zucchi A, Mearini L, Mearini E, Costantini E, Vivacqua C, Porena M. Renal cell carcinoma: histological findings on surgical margins after nephron sparing surgery. J Urol. 2003;169(3):905–8.CrossRefPubMed

16.

Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol. 2002;167(1):61–4.CrossRefPubMed

17.

Akcetin Z, Zugor V, Elsasser D, Krause FS, Lausen B, Schrott KM, Engehausen DG. Does the distance to normal renal parenchyma (DTNRP) in nephron-sparing surgery for renal cell carcinoma have an effect on survival? Anticancer Res. 2005;25(3a):1629–32.PubMed

18.

Berdjis N, Hakenberg OW, Zastrow S, Oehlschlager S, Novotny V, Wirth MP. Impact of resection margin status after nephron-sparing surgery for renal cell carcinoma. BJU Int. 2006;97(6):1208–10.CrossRefPubMed

19.

Chen XS, Zhang ZT, Du J, Bi XC, Sun G, Yao X. Optimal surgical margin in nephron-sparing surgery for T1b renal cell carcinoma. Urology. 2012;79(4):836–9.CrossRefPubMed

20.

Laganosky DD, Filson CP, Master VA. Surgical margins in nephron-sparing surgery for renal cell carcinoma. Current Urol Rep. 2017;18(1):8.CrossRef

21.

Richstone L, Scherr DS, Reuter VR, Snyder ME, Rabbani F, Kattan MW, Russo P. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol. 2004;171(2 Pt 1):615–20.CrossRefPubMed

22.

Whang M, O’Toole K, Bixon R, Brunetti J, Ikeguchi E, Olsson CA, Sawczuk TS, Benson MC. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol. 1995;154(3):968–70 (discussion 970–961).CrossRefPubMed

23.

Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001;166(1):6–18.CrossRefPubMed

24.

Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol. 1995;153(3 Pt 2):904–6.PubMed

25.

Baltaci S, Orhan D, Soyupek S, Beduk Y, Tulunay O, Gogus O. Influence of tumor stage, size, grade, vascular involvement, histological cell type and histological pattern on multifocality of renal cell carcinoma. J Urol. 2000;164(1):36–9.CrossRefPubMed

26.

Sargin SY, Ekmekcioglu O, Arpali E, Altinel M, Voyvoda B. Multifocality incidence and accompanying clinicopathological factors in renal cell carcinoma. Urol Int. 2009;82(3):324–9.CrossRefPubMed

27.

Zhang K, Xie WL. Determination of the safe surgical margin for T1b renal cell carcinoma. Urol J. 2017;14(1):2961–7.PubMed

Title: Histopathologic analysis of stage pT1b kidney neoplasms for optimal surgical margins of nephron-sparing surgery
Authors: G. Li
Q. Luo
Z. Lang
Y. Li
A. Wang
K. Wang
Y. Niu
Publication date: 01-09-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 9/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1845-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2018

Integral nutritional approach to the care of cancer patients: results from a Delphi panel

Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger

Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Circular RNAs and exosomes in cancer: a mysterious connection

Pancreaticoduodenectomy for periampullary tumours: a review article based on Surveillance, End Results and Epidemiology (SEER) database

Cancer and aging in Ibero-America

Keynote webinar | Spotlight on antibody–drug conjugates in cancer